The Californian company is leveraging its expertise in E3 ligases, a broad class of enzymes that can modulate proteins within the cell, together with proprietary DNA-encoded libraries and integrated discovery platforms.

Nurix’s wholly-owned, clinical stage pipeline includes targeted protein degraders of Bruton’s tyrosine kinase, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene B, an E3 ligase that regulates activation of multiple immune cell types including T cell and NK cells.